Komori
Changes in Officers4882Perseus Proteomics Inc.Pharmaceuticals

Notice Regarding Changes in Officers

Subject to approval at the Annual General Meeting of Shareholders, 1 director and 2 outside directors serving as Audit & Supervisory Committee Members will be newly appointed, while 1 director and 2 Audit & Supervisory Committee Members are scheduled to retire.

Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Who is moving to which position

Resolved 20 May 2026

Incoming appointee

3 items
Scheduled Appointment DateTo be formally determined upon approval at the 26th Annual General Meeting of Shareholders, scheduled for 24 June 2026
Tanahashi Susumu (棚橋 進)
Previous positionThe Company’s General Manager of the Business Development Department (current), and the Company’s Executive Officer and Deputy General Manager of the Administration Department (current)
New positionDirector, General Manager of the Administration Department and General Manager of the Business Development Department (newly appointed)
生年月日 13 February 1963入社年 2025所有株式数 - shares (record date: Not disclosed)
Matsumoto Hisashi (松本 尚)
Previous positionInvestment Partner at イノベーション・エンジン株式会社 (current)
New positionDirector and Audit & Supervisory Committee Member (newly appointed)
生年月日 12 November 1962入社年 Not disclosed所有株式数 - shares (record date: Not disclosed)
Nishigaki Fusako (西垣 扶佐子)
Previous positionLife Sciences Coordinator at 株式会社産学連携研究所 (current), Advisor at メディカルグローン株式会社 (current), and Advisor, Drug Discovery, at UntroD Capital Japan株式会社 (current)
New positionDirector and Audit & Supervisory Committee Member (newly appointed)
生年月日 14 September 1959入社年 Not disclosed所有株式数 - shares (record date: Not disclosed)

Departing officer

3 items
Date of departureTo be formally determined upon approval at the 26th Annual General Meeting of Shareholders, scheduled for 24 June 2026
Suzukawa Shinichi (鈴川 信一)Stepping down
Former PositionDirector and General Manager of the Administration Department
Nagakiyo Tatsuya (長清 達矢)Stepping down
Former PositionDirector serving as a full-time Audit & Supervisory Committee Member
Horiuchi Tadashi (堀内 正)Stepping down
Former PositionDirector serving as Audit and Supervisory Committee Member
Whether the incumbent will remain in office (whether they will retain their position)

Will not remain on the Board of Directors

Filing as an independent officerMatsumoto Hisashi (松本 尚) and Nishigaki Fusako (西垣 扶佐子) are candidates for independent officers
Shareholders’ meeting approvalRequired. The proposal is for the election of director candidates and director candidates who are Audit & Supervisory Committee Members. The scheduled meeting date is 24 June 2026
Independent officers are outside officers registered with the exchange as having no conflict of interest with general shareholders.
Who is moving to which position
ItemDetails
Resolution date20 May 2026
Scheduled Appointment DateTo be formally determined upon approval at the 26th Annual General Meeting of Shareholders, scheduled for 24 June 2026
Date of departureTo be formally determined upon approval at the 26th Annual General Meeting of Shareholders, scheduled for 24 June 2026
Name of appointeeTanahashi Susumu (棚橋 進), Matsumoto Hisashi (松本 尚), Nishigaki Fusako (西垣 扶佐子)
Appointee's new positionDirector, General Manager of the Administration Department and General Manager of the Business Development Department (newly appointed), Director and Audit & Supervisory Committee Member (newly appointed), Director and Audit & Supervisory Committee Member (newly appointed)
Appointee's previous positionThe Company’s General Manager of the Business Development Department (current), and the Company’s Executive Officer and Deputy General Manager of the Administration Department (current), Investment Partner at イノベーション・エンジン株式会社 (current), Life Sciences Coordinator at 株式会社産学連携研究所 (current), Advisor at メディカルグローン株式会社 (current), and Advisor, Drug Discovery, at UntroD Capital Japan株式会社 (current)
Appointee's date of birth13 February 1963, 12 November 1962, 14 September 1959
Year the appointee joined the Company2025, Not disclosed, Not disclosed
Number of shares held by the appointee- shares (record date: Not disclosed), - shares (record date: Not disclosed), - shares (record date: Not disclosed)
Name of departing officerSuzukawa Shinichi (鈴川 信一), Nagakiyo Tatsuya (長清 達矢), Horiuchi Tadashi (堀内 正)
Former position of departing officerDirector and General Manager of the Administration Department, Director serving as a full-time Audit & Supervisory Committee Member, Director serving as Audit and Supervisory Committee Member
Whether the incumbent will remain in officeWill not remain on the Board of Directors
Filing as an independent officerMatsumoto Hisashi (松本 尚) and Nishigaki Fusako (西垣 扶佐子) are candidates for independent officers
Subject to Approval by the General Meeting of ShareholdersRequired. The proposal is for the election of director candidates and director candidates who are Audit & Supervisory Committee Members. The scheduled meeting date is 24 June 2026
Items this document does not state (7)
New position of departing officerReason for departureReason for changeReasons for appointmentNumber of directors after the changeDetails of organizational changesChange in Corporate Governance Structure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No specific reason for the changes in directors is provided.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Changes in Officers | Perseus Proteomics Inc. (4882) timely disclosure | Komori